JP2014529613A5 - - Google Patents

Download PDF

Info

Publication number
JP2014529613A5
JP2014529613A5 JP2014527357A JP2014527357A JP2014529613A5 JP 2014529613 A5 JP2014529613 A5 JP 2014529613A5 JP 2014527357 A JP2014527357 A JP 2014527357A JP 2014527357 A JP2014527357 A JP 2014527357A JP 2014529613 A5 JP2014529613 A5 JP 2014529613A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
seq
haloalkyl
amyloid beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014527357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014529613A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014529613A publication Critical patent/JP2014529613A/ja
Publication of JP2014529613A5 publication Critical patent/JP2014529613A5/ja
Pending legal-status Critical Current

Links

JP2014527357A 2011-08-25 2012-08-27 神経変性疾患を治療する組成物及び方法 Pending JP2014529613A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161527584P 2011-08-25 2011-08-25
US61/527,584 2011-08-25
US201161527963P 2011-08-26 2011-08-26
US61/527,963 2011-08-26

Publications (2)

Publication Number Publication Date
JP2014529613A JP2014529613A (ja) 2014-11-13
JP2014529613A5 true JP2014529613A5 (cg-RX-API-DMAC7.html) 2016-03-31

Family

ID=47747106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014527357A Pending JP2014529613A (ja) 2011-08-25 2012-08-27 神経変性疾患を治療する組成物及び方法

Country Status (11)

Country Link
US (2) US20140378460A1 (cg-RX-API-DMAC7.html)
EP (1) EP2747768A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014529613A (cg-RX-API-DMAC7.html)
CN (2) CN107260726A (cg-RX-API-DMAC7.html)
AU (2) AU2012298617B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014004416A2 (cg-RX-API-DMAC7.html)
CA (1) CA2846611A1 (cg-RX-API-DMAC7.html)
HK (1) HK1202246A1 (cg-RX-API-DMAC7.html)
IL (1) IL231158A0 (cg-RX-API-DMAC7.html)
RU (1) RU2014111078A (cg-RX-API-DMAC7.html)
WO (1) WO2013029060A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013029057A2 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
ES2769780T3 (es) * 2013-10-28 2020-06-29 Univ Drexel Tratamientos novedosos para los trastornos de atención y cognitivos y para la demencia asociada a un trastorno neurodegenerativo
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
US10457642B2 (en) 2015-05-04 2019-10-29 The Trustees Of The University Of Pennsylvania 211-astatine containing radiotherapeutics for the treatment of cancer
US11617734B2 (en) * 2015-07-22 2023-04-04 Anavex Life Sciences Corp. Enantiomers of A2-73, analogues, and sigma agonist activity
CN110662532A (zh) * 2017-04-03 2020-01-07 加利福尼亚大学董事会 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs)
CN106986836A (zh) * 2017-04-26 2017-07-28 毛阿龙 具有抗细菌活性的新型速激肽拮抗剂的制备方法
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
WO2021064610A1 (en) * 2019-10-01 2021-04-08 Ac Immune Sa Micro-radiobinding assays for ligand screening
CN116867488A (zh) * 2020-12-11 2023-10-10 考格尼申治疗股份有限公司 用于治疗干性老年性黄斑变性(amd)的组合物
CN112816533A (zh) * 2020-12-31 2021-05-18 商丘师范学院 一种铜纳米簇作为电化学信号探针的β-淀粉样蛋白寡聚体传感器
WO2026030341A1 (en) 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease
WO2026136732A1 (en) 2024-12-18 2026-06-25 Cognition Therapeutics, Inc. Compositions and methods for the treatment of dementia with lewy bodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030038A1 (en) * 1996-02-15 1997-08-21 Mitsubishi Chemical Corporation Diarylsultam derivatives
EP1635805A4 (en) * 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
US20080153917A1 (en) * 2004-09-10 2008-06-26 Ucb Pharma, S.A. Sigma Receptor Ligands
ITRM20060007A1 (it) * 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
WO2010088450A2 (en) * 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
WO2010118055A1 (en) * 2009-04-09 2010-10-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
RU2012107457A (ru) * 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
US20130071330A1 (en) * 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith

Similar Documents

Publication Publication Date Title
ES2649155T3 (es) Anticuerpos anti-OX40 y procedimientos de uso de los mismos
JP2014524482A5 (cg-RX-API-DMAC7.html)
Fang et al. Gradients of the signaling lipid S1P in lymph nodes position natural killer cells and regulate their interferon-γ response
JP2019059786A5 (cg-RX-API-DMAC7.html)
ES2865023T3 (es) Anticuerpo anti-lipoarabinomanano e inmunoensayo para detectar la infección por bacilos acidorresistentes usando el anticuerpo
JP2014508748A5 (cg-RX-API-DMAC7.html)
CN105050621B (zh) 防止和治疗多发性硬化症的方法
JP6768728B2 (ja) ヒト抗体ならびに神経疾患の処置のためのその診断的および治療的使用
RU2017105515A (ru) Сигнальная система
RU2014111078A (ru) Композиции и способы для лечения нейродегенеративного заболевания
HRP20140240T4 (hr) Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
JP2013538796A5 (cg-RX-API-DMAC7.html)
CN105979962A (zh) 使用抗Aβ抗体减少脑淀粉样蛋白斑块的方法
JP2016509585A5 (cg-RX-API-DMAC7.html)
JP2013506425A5 (cg-RX-API-DMAC7.html)
CN104379167B (zh) 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列
EP3307320A2 (en) Stable formulations of humanized anti-tau antibody
JP2017511377A5 (cg-RX-API-DMAC7.html)
CN101374514A (zh) 神经元烟碱性受体配体和它们的用途
Cheng et al. The glomerulus–a view from the outside–the podocyte
Ciprés-Flores et al. Beta-blockers and salbutamol limited emotional memory disturbance and damage induced by orchiectomy in the rat hippocampus
JP2017520562A5 (cg-RX-API-DMAC7.html)
Jun et al. Clinical features and treatment outcome of primary systemic light‐chain amyloidosis in Korea: Results of multicenter analysis
Hori et al. Why does the progression of Alzheimer’s disease accelerate
Ma et al. Expression of noradrenergic α1, serotoninergic 5HT2a and dopaminergic D2 receptors on neurons activated by typical and atypical antipsychotic drugs